Axogen (AXGN) vs EDAP TMS S.A. (FOCL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Axogen (AXGN) has outperformed EDAP TMS S.A. (FOCL) over the past year, gaining 120.0% versus a gain of 93.1%. Over five years, AXGN leads with a +165.3% price change compared with -30.7% for FOCL. Axogen is the larger company by market cap ($2.12 billion vs $197.8 million), about 10.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXGN | FOCL |
|---|---|---|
| Share price | $36.13 | $4.19 |
| Market cap | $2.12B | $197.84M |
| 1-day change | -0.14% | +1.58% |
| YTD return | +10.39% | +27.36% |
| 1-year return | +120.04% | +93.09% |
| 5-year return | +165.27% | -30.74% |
| Forward P/E | 50.30 | — |
| EPS (TTM) | $-0.67 | $-1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $225.21M | — |
| Revenue growth (YoY) | +20.21% | — |
| Net income (latest FY) | $-15.70M | — |
| Gross margin | 74.31% | — |
| Operating margin | -3.49% | — |
| Net margin | -6.97% | — |
| 52-week high | $52.91 | $6.40 |
| 52-week low | $15.27 | $1.75 |
| Distance from 52-week high | -31.71% | -34.53% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +48.96% | +110.02% |
| Average volume | 1.21M | 115.89K |
| Shares outstanding | 58.67M | 47.22M |
| Employees | 622 | 289 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Axogen is about 10.7 times larger than EDAP TMS S.A. by market value ($2.12B vs $197.84M).
- AXGN has outperformed FOCL by 26.9 percentage points over the past year.
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees
About EDAP TMS S.A.
FOCL stock →EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 289 employees
AXGN vs FOCL FAQ
Which is bigger, Axogen or EDAP TMS S.A.?
Axogen (AXGN) is larger, with a market capitalization of $2.12B compared with $197.84M for EDAP TMS S.A. (FOCL).
Which stock has performed better over the past year, AXGN or FOCL?
AXGN returned +120.04% over the past 12 months, compared with +93.09% for FOCL (price return, excluding dividends). Past performance does not predict future results.
Are Axogen and EDAP TMS S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.